Mandatory Documents to be submitted for import of ayurvedic drugs

INTRODUCTION
In India, the regulatory framework for Ayurvedic drugs has remained unclear, as the forms prescribed under the Drugs Rules, 1945 (“Drugs Rules”) for obtaining an import license are not appropriate for Ayurvedic drugs.
The Madras High Court in the case of M/s Axeon Marketing India v. Assistant Commissioner of Customs has clarified the steps to be followed for the import of Ayurvedic drugs into India.
In this article we have listed the documents required and steps to be followed for the import of ayurvedic drugs into India.

The following are the essential steps to be followed, along with the required documents:

1. Submission of regulatory documents
Despite the absence of specific licensing forms, importers should proceed by compiling a comprehensive documentation to present to Customs authorities and the State Licensing Authority (“SLA”). This should include:
– Copy of invoice
– Packing list which includes the details of contents of each package
– Manufacturer’s test report
– Manufacturing license (from the country of origin)
– Specimen sample
– Label (The label must comply with the labelling requirements given under Rule 161 of the Drugs Rules.)

2. Testing by Central Drugs Standard Control Organization-accredited laboratory (“CDSCO lab”)
It is now mandatory that imported Ayurvedic drugs be tested at a CDSCO lab in India to ensure compliance with Indian safety and quality standards. The imported drug must meet standards equivalent to those applicable to similar Ayurvedic drugs already manufactured and approved in India.
– The importer is required to submit imported drug samples to a CDSCO lab, where testing will be conducted under the supervision of SLA of the state in which the laboratory is located.
– The cost for testing will be borne by the Indian importer
– If a satisfactory report is received from such laboratory, the concerned SLA will issue a certificate confirming that the manufacturing process of the imported drugs is in conformity with the process prescribed for the manufacture of ayurvedic drugs in India.

3. Submission of certificate issues by SLA
– A copy of the certificate issued by the SLA must be submitted to the Customs Department.

4. Receipt of Assistant Drug Controller’s No Objection Certificate (“NOC”)
– This document is issued by the port office of CDSCO.
– The NOC indicates that the consignment meets all applicable regulatory requirements
– Invoice, packing list, manufacture’s test report, manufacturing license, specimen sample, label may be examined before giving NOC by port office.

CONCLUSION
A guidance document governing the import of Ayurvedic drugs already existed, however, it did not mandate testing of the imported drug by a CDSCO lab. After the recent judgment by the Hon’ble Madras High Court, this requirement has now been made compulsory. Therefore, importers must comply with this requirement, along with all other steps outlined above, to obtain import clearance.

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. we hope you enjoy reading it.

1. Maharashtra Health Minister has reportedly announced reforms for increased hospital safety such as independent third-party testing of medicines supplied to state hospitals. Other proposed reforms include stricter oversight on medicine procurement, manpower increase in Maharashtra Medical Goods Procurement Agency (MMGPA) and enhanced enforcement of the Bombay Nursing Act. Plans for regulating private labs, flying squads for inspections, and public hospital makeovers with standardised designs were also announced.
Source: bit.ly/3DE8QQy

2. The Central Pollution Control Board (CPCB) has issued show cause notices under the Environment (Protection) Act, 1986, to Producers, Importers, and Brand Owners (PIBOs) for failing to meet Extended Producer Responsibility (EPR) obligations under the Plastic Waste Management Rules, 2016. Non-compliance includes not filing annual returns for FY 2022-23 and FY 2023-24 and falling short of EPR targets. Affected entities must respond within 7 days or face Environmental Compensation (EC) penalties and stricter enforcement measures.
Source: bit.ly/3W3Deua

3. The Indian Council of Medical Research (ICMR) has released the draft second edition of the National Essential Diagnostics List (NEDL), inviting stakeholder suggestions by January 15, 2025. The revised list aims to enhance diagnostic services across all healthcare levels, including Ayushman Arogya Mandirs, Primary Health Centres (PHCs), and Community Health Centres (CHCs) and Sub-District Hospitals (SDHs) with a focus on underserved areas. It aligns with national health programmes and incorporates technological advancements like point-of-care testing to ensure accessibility and affordability.
Source: bit.ly/4059Qor

4. The Indian Government (Ministry of Textiles) has issued the Medical Textile (Quality Control) Amendment Order 2025. This amendment states that if the manufacturer / importer certified by the Bureau or any manufacturer / importer who has applied for certification has declared its old stock products  which are without BIS  Mark manufactured or imported before the commencement of the timeline of implementation (mentioned below) of the order, such manufacturer / importer shall be permitted to sell or display to offer to sell such declared stock up to 30th June, 2025. The key timelines are as follows: For Large and Medium Enterprises: 1st January, 2025 ; For Small and Micro Enterprises: 1st April, 2025
Source: bit.ly/4fDZi5q

5. India’s Union Health Minister has banned the manufacturing and sale of Non-Steroidal Anti-Inflammatory Drug (NSAID) drug nimesulide for animal use due to its toxicity to vultures, causing mortality through visceral gout and renal failure. The ban follows recommendations by the Drugs Technical Advisory Board (DTAB) and studies by the Bombay Natural History Society (BNHS). Safer alternatives are available, and measures to prevent misuse of the drug in humans have been proposed.
Source: bit.ly/4fOz8Nk